Top

Published in:

01-06-2014 | Psychosis (R Gur and B Clementz, Section Editors)

Epigenetic Dysregulation in the Schizophrenic Brain

Authors: Tobias B. Halene, Cyril J. Peter, Schahram Akbarian

Published in: Current Behavioral Neuroscience Reports | Issue 2/2014

Abstract

Schizophrenia (SCZ) is a severe psychiatric disorder, which lacks a unifying neuropathology. However, reproducible molecular alterations exist, including RNA expression changes affecting GABAergic and other neuronal signaling in cerebral cortex, myelination, and other cellular functions. Yet, for the large majority of RNAs altered in the SCZ brain, the underlying transcriptional and post-transcriptional disease-associated mechanisms remain unclear. Here, we provide an update on epigenetic regulators of gene expression that are potentially affected in some cases with SCZ, including DNA cytosine methylation, histone modifications and histone variants, and chromosomal loop formations facilitating long-range interactions of gene promoters with distal enhancer elements. Exploration of chromatin structure and function, in combination with transcriptome and genome sequencing, is likely to critically advance insight into the molecular mechanisms of disease in specific cases with SCZ.

Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.PubMed

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.PubMed

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164(3):428–36.PubMed

Taly A. Novel approaches to drug design for the treatment of schizophrenia. Expert Opin Drug Disc. 2013;8(10):1285–96.

Kim DH, Stahl SM. Antipsychotic drug development. Curr Top Behav Neurosci. 2010;4:123–39.PubMed

Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm. 2009;116(3):275–89.PubMed

Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res. 2007;151(3):179–88.PubMed

Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res. 2005;79(2–3):157–73.PubMed

Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res. 2004;77(6):858–66.PubMed

10.

Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98(8):4746–51.PubMedCentralPubMed

11.

Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362(9386):798–805.PubMed

12.

Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon WC. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res. 2010;44(10):673–81.PubMed

13.

Charych EI, Liu F, Moss SJ, Brandon NJ. GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology. 2009;57(5–6):481–95.PubMedCentralPubMed

14.

Woo TU, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. 2008;1218:267–77.PubMedCentralPubMed

15.

Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52(2):293–304.PubMed

16.

Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology. 2005;180(2):191–205.PubMed

17.

Dracheva S, Elhakem SL, McGurk SR, Davis KL, Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res. 2004;76(4):581–92.PubMed

18.

Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry. 2008;165(4):479–89.PubMedCentralPubMed

19.

Benes FM. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology. 2010;35(1):239–57.PubMedCentralPubMed

20.

Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007;32(9):1888–902.PubMed

21.

Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev. 2000;31(2–3):288–94.PubMed

22.

Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry. 2002;59(7):631–40.PubMed

23.

Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28(1):53–67.PubMed

24.

Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002;22(7):2718–29.PubMed

25.

Uhlhaas PJ, Singer W. Neuronal dynamics and neuropsychiatric disorders: toward a translational paradigm for dysfunctional large-scale networks. Neuron. 2012;75(6):963–80.PubMed

26.

Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35(1):57–67.PubMedCentralPubMed

27.

Zhang Y, Behrens MM, Lisman JE. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol. 2008;100(2):959–65.PubMedCentralPubMed

28.

Fatemi SH, Stary JM, Earle JA, Araghi-Niknam M, Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res. 2005;72(2–3):109–22.PubMed

29.

Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney Jr WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995;52(4):258–66.PubMed

30.

Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H, et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res. 2011;131(1–3):165–73.PubMedCentralPubMed

31.

Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57(11):1061–9.PubMed

32.

Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2004;61(7):649–57.PubMed

33.

Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK + and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci. 2011;36(3):195–203.PubMed

34.

Volk DW, Matsubara T, Li S, Sengupta EJ, Georgiev D, Minabe Y, et al. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am J Psychiatry. 2012;169(10):1082–91.PubMedCentralPubMed

35.

Huang HS, Matevossian A, Jiang Y, Akbarian S. Chromatin immunoprecipitation in postmortem brain. J Neurosci Methods. 2006;156(1–2):284–92.PubMed

36.

Ernst C, McGowan PO, Deleva V, Meaney MJ, Szyf M, Turecki G. The effects of pH on DNA methylation state: In vitro and post-mortem brain studies. J Neurosci Methods. 2008;174(1):123–5.PubMed

37.

Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324(5929):929–30.PubMedCentralPubMed

38.

Xie W, Barr CL, Kim A, Yue F, Lee AY, Eubanks J, et al. Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome. Cell. 2012;148(4):816–31.PubMedCentralPubMed

39.

Jin SG, Wu X, Li AX, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 2011;39(12):5015–24.PubMedCentralPubMed

40.

Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29(1):68–72.PubMedCentralPubMed

41.

Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell. 2012;151(7):1417–30.PubMedCentralPubMed

42.

Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol. 2012;19(10):1037–43.PubMedCentralPubMed

43.

Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466(7303):253–7.PubMedPubMedCentral

44.

Sharma RP, Grayson DR, Guidotti A, Costa E. Chromatin, DNA methylation and neuron gene regulation: the purpose of the package. J Psychiatry Neurosci. 2005;30(4):257–63.PubMedCentralPubMed

45.

Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):60–6.PubMed

46.

Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A. 2005;102(26):9341–6.PubMedCentralPubMed

47.

Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15(21):3132–45.PubMedCentralPubMed

48.

Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci. 2005;25(22):5376–81.PubMed

49.

Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL, et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry. 2014;4:e339.PubMedCentralPubMed

50.•

Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82(3):696–711. This is the first study to profile DNA methylation changes on a genome-wide scale in the postmortem schizophrenic brain.PubMedCentralPubMed

51.

Tochigi M, Iwamoto K, Bundo M, Komori A, Sasaki T, Kato N, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63(5):530–3.PubMed

52.

Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PloS One. 2007;2(9):e895.PubMedCentralPubMed

53.

Marutha Ravindran CR, Ticku MK. Changes in methylation pattern of NMDA receptor NR2B gene in cortical neurons after chronic ethanol treatment in mice. Brain Res Mol Brain Res. 2004;121(1–2):19–27.PubMed

54.

Satta R, Maloku E, Zhubi A, Pibiri F, Hajos M, Costa E, et al. Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A. 2008;105(42):16356–61.PubMedCentralPubMed

55.

Satta R, Maloku E, Costa E, Guidotti A. Stimulation of brain nicotinic acetylcholine receptors (nAChRs) decreases DNA methyltransferase 1 (DNMT1) expression in cortical and hippocampal GABAergic neurons of Swiss albino mice. Society for Neuroscience Abstract. 2007.

56.

Numachi Y, Shen H, Yoshida S, Fujiyama K, Toda S, Matsuoka H, et al. Methamphetamine alters expression of DNA methyltransferase 1 mRNA in rat brain. Neurosci Lett. 2007;414(3):213–7.PubMed

57.

Numachi Y, Yoshida S, Yamashita M, Fujiyama K, Naka M, Matsuoka H, et al. Psychostimulant alters expression of DNA methyltransferase mRNA in the rat brain. Ann N Y Acad Sci. 2004;1025:102–9.PubMed

58.

Numata S, Ye T, Hyde TM, Guitart-Navarro X, Tao R, Wininger M, et al. DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet. 2012;90(2):260–72.PubMedCentralPubMed

59.

Zhang D, Cheng L, Badner JA, Chen C, Chen Q, Luo W, et al. Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet. 2010;86(3):411–9.PubMedCentralPubMed

60.••

Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature. 2011;478(7370):519–23. This is a comprehensive study on gene expression profiles across the lifespan of the prefrontal cortex, using hundreds of postmortem brain specimens.PubMedCentralPubMed

61.

Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146(6):1016–28.PubMedCentralPubMed

62.

Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705.PubMed

63.

Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14(11):1025–40.PubMed

64.•

Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7–18. This paper provides an excellent overview on the assocation of specific types of histone modifications with chromatin structures and function.PubMed

65.

Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–12.PubMed

66.

Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 2004;20(4):214–20.PubMed

67.

Li J, Guo Y, Schroeder FA, Youngs RM, Schmidt TW, Ferris C, et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem. 2004;90(5):1117–31.PubMed

68.

Tang B, Dean B, Thomas EA. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl Psychiatry. 2011;1:e64.PubMedCentralPubMed

69.

Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27(42):11254–62.PubMed

70.

Zhang TY, Hellstrom IC, Bagot RC, Wen X, Diorio J, Meaney MJ. Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. J Neurosci. 2010;30(39):13130–7.PubMed

71.

Mackowiak M, Bator E, Latusz J, Mordalska P, Wedzony K. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol. 2014;24(2):271–89.PubMed

72.

Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15(9):1245–54.PubMedCentralPubMed

73.

Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E, et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother. 2009;9(1):87–98.PubMed

74.

Aoyama Y, Mouri A, Toriumi K, Koseki T, Narusawa S, Ikawa N, et al. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol. 2013:1-15.

75.

Kano S, Colantuoni C, Han F, Zhou Z, Yuan Q, Wilson A, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18(7):740–2.PubMedCentralPubMed

76.

Woodcock CL. Chromatin architecture. Curr Opin Struct Biol. 2006;16(2):213–20.PubMed

77.

Jin C, Felsenfeld G. Nucleosome stability mediated by histone variants H3.3 and H2A.Z. Genes Dev. 2007;21(12):1519–29.PubMedCentralPubMed

78.

Sutcliffe EL, Parish IA, He YQ, Juelich T, Tierney ML, Rangasamy D, et al. Dynamic histone variant exchange accompanies gene induction in T cells. Mol Cell Biol. 2009;29(7):1972–86.PubMedCentralPubMed

79.

Bintu L, Kopaczynska M, Hodges C, Lubkowska L, Kashlev M, Bustamante C. The elongation rate of RNA polymerase determines the fate of transcribed nucleosomes. Nat Struct Mol Biol. 2011;18(12):1394–9.PubMedCentralPubMed

80.

Sanders AR, Goring HH, Duan J, Drigalenko EI, Moy W, Freda J, et al. Transcriptome study of differential expression in schizophrenia. Hum Mol Genet. 2013;22(24):5001–14.PubMed

81.

Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460(7256):753–7.PubMedCentralPubMed

82.

Rodriguez-Campos A, Azorin F. RNA is an integral component of chromatin that contributes to its structural organization. PloS One. 2007;2(11):e1182.PubMedCentralPubMed

83.

Brockdorff N. Noncoding RNA, and Polycomb recruitment. RNA. 2013;19(4):429–42.PubMedCentralPubMed

84.

Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science. 2008;322:750–6.PubMedCentralPubMed

85.

Leung KN, Chamberlain SJ, Lalande M, LaSalle JM. Neuronal chromatin dynamics of imprinting in development and disease. J Cell Biochem. 2011;112(2):365–73.PubMedCentralPubMed

86.

Le Meur E, Watrin F, Landers M, Sturny R, Lalande M, Muscatelli F. Dynamic developmental regulation of the large non-coding RNA associated with the mouse 7C imprinted chromosomal region. Dev Biol. 2005;286(2):587–600.PubMed

87.

Xin Z, Allis CD, Wagstaff J. Parent-specific complementary patterns of histone H3 lysine 9 and H3 lysine 4 methylation at the Prader-Willi syndrome imprinting center. Am J Hum Genet. 2001;69(6):1389–94.PubMedCentralPubMed

88.

Zaaroor-Regev D, de Bie P, Scheffner M, Noy T, Shemer R, Heled M, et al. Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc Natl Acad Sci U S A. 2010;107(15):6788–93.PubMedCentralPubMed

89.

Vogel T, Stoykova A, Gruss P. Differential expression of polycomb repression complex 1 (PRC1) members in the developing mouse brain reveals multiple complexes. Dev Dyn. 2006;235(9):2574–85.PubMed

90.

Tarabykin V, Britanova O, Fradkov A, Voss A, Katz LS, Lukyanov S, et al. Expression of PTTG and prc1 genes during telencephalic neurogenesis. Mech Dev. 2000;92(2):301–4.PubMed

91.

Golden MG, Dasen JS. Polycomb repressive complex 1 activities determine the columnar organization of motor neurons. Genes Dev. 2012;26(19):2236–50.PubMedCentralPubMed

92.

Ronan JL, Wu W, Crabtree GR. From neural development to cognition: unexpected roles for chromatin. Nat Rev Genet. 2013;14(5):347–59.PubMed

93.

Vogel-Ciernia A, Wood MA. Neuron-specific chromatin remodeling: a missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacol. 2013.

94.

Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K, et al. Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet. 2009;18(13):2483–94.PubMed

95.

Cremer T, Cremer C. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat Rev Genet. 2001;2(4):292–301.PubMed

96.

Duan Z, Andronescu M, Schutz K, McIlwain S, Kim YJ, Lee C, et al. A three-dimensional model of the yeast genome. Nature. 2010;465(7296):363–7.PubMedCentralPubMed

97.

Wood AJ, Severson AF, Meyer BJ. Condensin and cohesin complexity: the expanding repertoire of functions. Nat Rev Genet. 2010;11(6):391–404.PubMedCentralPubMed

98.

Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet. 2006;7(9):703–13.PubMed

99.

Jin F, Li Y, Dixon JR, Selvaraj S, Ye Z, Lee AY, et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature. 2013;503(7475):290–4.PubMed

100.

Moss JF, Oliver C, Berg K, Kaur G, Jephcott L, Cornish K. Prevalence of autism spectrum phenomenology in Cornelia de Lange and Cri du Chat syndromes. Am J Ment Retard. 2008;113(4):278–91.PubMed

101.

Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature. 2012;489(7415):313–7.PubMedCentralPubMed

102.

Gervasini C, Parenti I, Picinelli C, Azzollini J, Masciadri M, Cereda A, et al. Molecular characterization of a mosaic NIPBL deletion in a Cornelia de Lange patient with severe phenotype. Eur J Med Gene. 2013;56(3):138–43.

103.

Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467(7314):430–5.PubMedCentralPubMed

104.•

Mitchell AC, Bharadwaj R, Whittle C, Krueger W, Mirnics K, Hurd Y, et al. The genome in three dimensions: a new frontier in human brain research. Biol Psychiatry. 2013. This paper provides detailed protocols to map 3-dimensional genome architecture and chromosomal conformatins in postmortem brain specimens.

105.••

Bharadwaj R, Jiang Y, Mao W, Jakovcevski M, Dincer A, Krueger W, et al. Conserved chromosome 2q31 conformations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia. J Neurosci. 2013;33(29):11839–51. This is the first paper to map chromosomal loop formations in postmortem brain of subjects with schizophrenia.PubMedCentralPubMed

106.

Shulha HP, Cheung I, Whittle C, Wang J, Virgil D, Lin CL, et al. Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch Gen Psychiatry. 2012;69(3):314–24.PubMed

107.

Bundo M, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi T, et al. Increased L1 retrotransposition in the neuronal genome in schizophrenia. Neuron. 2014;81(2):306–13.PubMed

Title: Epigenetic Dysregulation in the Schizophrenic Brain
Authors: Tobias B. Halene
Cyril J. Peter
Schahram Akbarian
Publication date: 01-06-2014
Publisher: Springer International Publishing
Published in: Current Behavioral Neuroscience Reports / Issue 2/2014
Electronic ISSN: 2196-2979
DOI: https://doi.org/10.1007/s40473-014-0007-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epigenetic Dysregulation in the Schizophrenic Brain

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Vagus Nerve Stimulation

Toward an Understanding of the Neural Circuitry of Major Depressive Disorder Through the Clinical Response to Deep Brain Stimulation of Different Anatomical Targets

Early Detection of Psychosis: Challenges and Opportunities

Transcranial Direct Current Stimulation (tDCS): Modulation of Executive Function in Health and Disease

Animal Models of Psychosis: Current State and Future Directions

The Future of Psychoses as Seen from the History of its Evolution